Opiant Pharmaceuticals Inc

Opiant Pharmaceuticals — Investor Presentation (September 2017)

39 slides from Opiant Pharmaceuticals's investor presentation, Sep 12, 2017

  1. Slide 1: Focused on Addiction

    FOCUSED ON ADDICTION Company Presentation September 2017 NASDAQ: OPNT

  2. Slide 2: Forward Looking Statement

    Forward Looking Statement 2 This presentation contains ‘forward - looking statements’ within the meaning of Section of the Securities Act of 1933 as amended, and Section 21E of the Securities Exchange Act of 1934 as amended. These forward - looking statements relate to future events or our future fi

  3. Slide 3: OPNT: Focused on Addiction

    3 OPNT: Focused on Addiction A Commercial - Stage Specialty Pharma Company Focused on Addiction Leveraging expertise, technology and a record of success to address the leading sources of addiction • Opioids • Alcohol • Food

  4. Slide 4: Lead Programs

    4 Lead Programs Indication Product Candidate / Regulatory Pathway Pre - clinical Phase 1 Phase 2 Phase 3 NDA FDA Approval Partner Opioid Overdose NARCAN® Nasal Spray 505(b)(2) Eating Disorders OPNT001 Opioid Antagonist Nasal Spray 505(b)(2) Alcohol Dependence OPNT002 Opioid Antagonist Nasal Spray /

  5. Slide 5: Management Team

    Arvind Agrawal MSc EVP, Medical Affairs Extensive addiction and CNS drug development experience Dr. Roger Crystal MD MRCS MBA Chief Executive Officer David O’Toole , CPA Chief Financial Officer Mark Ellison, Ph.D. EVP Development, Manufacturing and Quality Dr. Phil Skolnick Ph.D   D.Sc  hon  C

  6. Slide 6: Opiant aims to become a leading addiction biopharma

    Opiant aims to become a leading addiction biopharma developing drugs at low cost, and quick to market Replicate recent success Invest long term Deliver on first program • New programs • predominantly 505(b)(2), relatively low cost , low technical risk • primarily using nasal opioid antagonists • Lar

  7. Slide 7: Addressing Addiction

    Addressing Addiction @ Opiant

  8. Slide 8: Addiction has evolved as a disease, now more acceptable to treat with pharmacotherapy

    8 Addiction has evolved as a disease, and now more acceptable to treat with pharmacotherapy The Past: Addicts as “junkies”; The Present: Addiction now recognized as a brain disease The Future: Incorporate pharmacotherapy as standard of care

  9. Slide 9: Addiction now represents an attractive commercial opportunity

    Addiction now represents an attractive commercial opportunity 9 Strong sales from existing products • Suboxone sales > $1B • 27% growth in Vivitrol sales expected for 2017 - $250M Significant unmet need & increased government funding • Only 1 in 9 addicts receive appropriate treatment • Problem grow

  10. Slide 10: Addictions driven by reward center dopamine, blocked by opioid antagonists

    10 Addictions are driven by the brain’s reward center releasing dopamine which can be blocked by opioid antagonists

  11. Slide 11: Opioid antagonists act on breathing and reward centers

    Opioid antagonists acts on both the brain’s breathing and reward centers 11 Prior to OPNT001 2 time points after nasal administration of OPNT001

  12. Slide 12: Opioid antagonists validated as therapeutics with excellent safety profile

    12 Opioid antagonists have been validated as therapeutics with an excellent safety profile

  13. Slide 13: NARCAN Nasal Spray

    NARCAN® Nasal Spray @ Opiant

  14. Slide 14: Opioid addiction and overdose: a significant public health crisis

    14 Opioid addiction and overdose: A significant public health crisis • Opioid overdose deaths have increased dramatically since 2000 • Dramatic increase in synthetic opioids including fentanyl • Approximately opioid 33,000 overdose deaths in 2015

  15. Slide 15: Rise in overdose cases from more potent, longer lasting opioids

    A major issue is the rise in overdose cases from opioids more potent and longer lasting than heroin 15 Increasing overdose rates from 1. more potent opioids 2. longer acting opioids

  16. Slide 16: Naloxone saves lives if given quickly

    16 Naloxone saves lives if given quickly – injections can only be given by qualified personnel Dial 911 Await ambulance Patient already stopped breathing Help often arrives too late Opioid pain killers, heroin, or fentanyl: victim unresponsive( ± breathing)

  17. Slide 17: NARCAN Nasal Spray is the only FDA-approved naloxone nasal spray

    17 NARCAN® Nasal Spray is the only FDA - approved naloxone nasal spray for reversal of opioid overdose • Developed by Opiant • 2 doses now FDA approved • 6 FDA Orange Book patents • Licensed to Adapt Pharma in 2014 • Partial monetization deal with SWK: • OPNT received $17.5M, SWK receive next $26.25

  18. Slide 18: NARCAN Nasal Spray: rapid absorption with higher blood levels

    18 NARCAN® Nasal Spray: Rapid absorption with higher blood levels compared to 0.4mg injectable naloxone Time Post Administration (hour) Naloxone Concentration (ng/ml) Dose 3 – 0.4mg Intramuscular Dose 1 – 4mg Intranasal Dose 2 – 2mg Intranasal 6.0 5.0 4.0 3.0 2.0 1.0 0.0 0.0 0.5 1.0 1.5 2.0 2.5 3.0

  19. Slide 19: NARCAN Nasal Spray: easiest to use, needle free

    19 NARCAN® Nasal Spray – Easiest to use, needle free and among the least expensive Injectable Naloxone Autoinjectors Improvised Nasal Kits NARCAN® Nasal Spray • Only suitable for trained personnel • Requires prep time • Requires a needle • Expensive • Not needle free • Only suitable for trained pers

  20. Slide 20: Potential $2B addressable market in U.S.

    20 Over 20 million unique opioid users resulting in a potential $2B addressable market in U.S. *Opiant estimate of average selling price ** Co - prescribing starting to happen – mandatory in Vermont for high risk patients First Responders 1M patients with opioid use disorder taking methadone, suboxo

  21. Slide 21: NARCAN Nasal Spray becoming the mainstream rescue product

    21 NARCAN® Nasal Spray is becoming the mainstream rescue product across the USA

  22. Slide 22: Beyond Overdose: Addressing Chronic Treatment of Addictions

    Beyond Overdose … .Addressing Chronic Treatment of Addictions 22

  23. Slide 23: Leveraging NARCAN success to address larger addiction markets

    Opiant is leveraging NARCAN® success to address larger, broader addiction markets 12M 1.5M Opioid Overdose ~33k deaths per year Alcohol Use Disorder ~16 million Eating Disorders ~10 million Opioid Use Disorder ~2.4 million ACUTE CHRONIC 23

  24. Slide 24: OPNT002 for Alcohol Use Disorder (AUD)

    OPNT002 for Alcohol Use Disorder (AUD) 24

  25. Slide 25: Today's AUD medication requires abstinence and is poorly tolerated

    Today’s AUD medication requires abstinence and is poorly tolerated, so fewer than 5% of receive pharmacotherapy 25 patients with AUD currently receiving pharmacotherapy patients with AUD seeking treatment individuals in the USA meeting DSM - V diagnostic criteria for AUD 2.2M 15.7M 0.4M More effecti

  26. Slide 26: OPNT002 will be a differentiated product for AUD

    Combining targeted dosing with a harm reduction endpoint, OPNT002 will be a differentiated product for AUD 26 Need for abstinence prior to commencing medication Need for abstinence as only acceptable outcome Low adherence for existing medication OPNT002 taken whenever patients have the urge to drink

  27. Slide 27: Faster nasal absorption vs oral

    Faster nasal absorption vs oral Absorption of oral naltrexone is minimal at 5 - 10 minutes Rapid nasal absorption Vs oral, ensures that the maximum amount of drug is present when it is most needed 27 • Opioid receptors blocked when drinking alcohol • Patients can reduce heavy drinking Naltrexone blo

  28. Slide 28: Existing pharmacotherapies for AUD have limitations

    28 OPNT Existing Pharmacotherapies Criteria NASAL Naltrexone OPNT002 * Acamprosate (CAMPRAL) Disulfiram (ANTABUSE) Naltrexone HCl (Oral: ReVia ® / Generics) Naltrexone HCl (Injection: Vivitrol ®) “As - needed” use basis ✔ ✘ ✘ Can be used this way, but not current US practice ✘ Well - tolerated ✔ ✔ ✘

  29. Slide 29: Reduction in drinking is now an acceptable FDA outcome measure

    29 Reduction in drinking improves mortality and is now an acceptable outcome measure for FDA approval

  30. Slide 30: OPNT002 can transform AUD treatment and access

    Taken as needed, avoiding detox, OPNT002 can transform AUD treatment & access AUD patients in several settings 30 Avoids the need for detox, withdrawal Patients take the drug when needed – greater control over drinking Reduce drinking rather than abstinence (accepted by FDA, KOLs) AUD patients in tr

  31. Slide 31: FDA feedback supportive of OPNT002 development plan

    31 FDA feedback supportive of OPNT002 development plan alongside attractive commercial opportunity • Further development planned for 2H 2017 • 505(b)(2) regulatory pathway confirmed – increased likelihood and speed for FDA approval • Potential to self - commercialize and target treatment centers • M

  32. Slide 32: OPNT001 for Eating Disorders

    OPNT001 for Eating Disorders 32

  33. Slide 33: Eating disorders affect millions with only one drug approved per indication

    Eating disorders affect millions with only one drug approved in each indication 33 Bulimia Nervosa • Compulsive bingeing and purging • Severe complications if untreated • Fluoxetine only approved drug • Affects 2.5M people in USA • Mostly young women Binge Eating Disorder • Most common eating disord

  34. Slide 34: OPNT001 shows promise for Binge Eating Disorder

    164.8 171.3 174.8 179.9 188.6 199.9 0 - 40 - 80 - 120 - 160 - 180 Base 1 - 20 - 60 - 100 - 140 2 3 4 5 6 OPNT001 shows promise for Binge Eating Disorder 34 Proof of concept study (Helsinki) • (n=127) in patients with BED, Randomized, double blind, placebo controlled study • Significant reduction fro

  35. Slide 35: OPNT001 Phase 2 trial design for Bulimia Nervosa

    OPNT001 Phase 2 trial design for Bulimia Nervosa 35 • Randomized, double blind, placebo controlled study in the UK underway • 80 patients • Primary endpoint – reduction in binge eating days • Expected duration – 12 months (further guidance once patient recruitment underway) • Data readout expected Q

  36. Slide 36: Corporate

    Corporate @ Opiant

  37. Slide 37: Corporate/Clinical Milestones

    37 Corporate/Clinical Milestones Enhance corporate governance through establishment of Board committees (1Q 2017) Initiate of Phase 2 trial of OPNT001 in Bulimia Nervosa (2Q 2017) Listed on Nasdaq Capital Market Strengthen management team through appointment of a CSO (1Q 2017) Ongoing development of

  38. Slide 38: OPNT: Investment Highlights

    38 OPNT: Investment Highlights Record of commercialization in addiction, where others have failed High value pipeline, clinical and regulatory success in developing nasally - delivered opioid antagonists Significant competitive advantages and strong IP Strong partnerships and strengthened balance sh

  39. Slide 39: Focused on Addiction

    FOCUSED ON ADDICTION www.opiant.com

Opiant Pharmaceuticals — Investor Presentation (September 2017) on 6ix